|MDACC Study No:||2012-1047 (clinicaltrials.gov NCT No: NCT01892371)|
|Title:||Phase I/II Study of the Combination of Quizartinib (AC220) with 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|
|Principal Investigator:||Jorge Cortes|
|Treatment Agent:||5-Azacytidine; AC220; Cytarabine|
|Study Description:||The goal of the Phase 1 part of this clinical research study is to find the |
highest tolerable dose of AC220 (quizartinib) that can be given with either
5-azacitidine (azacitidine) or cytarabine to patients with AML or MDS.
The goal of the Phase 2 part of the study is to learn if quizartinib with
either azacitidine or cytarabine can help to control AML or MDS. The safety of
these combinations will also be studied.